Bimekizumab in patients with moderate to severe plaque psoriasis: Analysis of mental health and associated disorders

Bimekizumab efficacy in patients with moderate to severe plaque psoriasis and hypertension, elevated body mass index, or hyperglycemia: Results through 3 years of treatment in 5 phase 3/3b trials

Bimekizumab efficacy through 3 years in patients with moderate to severe plaque psoriasis: Long-term pooled analysis from BE BRIGHT

Management and treatment patterns in psoriasis and psoriatic arthritis

Bimekizumab efficacy and safety in biologic DMARD-naïve patients with psoriatic arthritis was consistent with or without methotrexate: 52-Week results from the Phase 3 active reference study BE OPTIMAL

Patients with psoriatic arthritis at biologic therapy switch: The CorEvitas psoriasis registry

A matching-adjusted indirect comparison of the efficacy of bimekizumab and guselkumab at 52 weeks for the treatment of psoriatic arthritis

Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumor necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year

Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials

Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials

Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials

Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials